Difluoromethylornithine rebalances aberrant polyamine ratios in Snyder-Robinson syndrome

ABSTRACT: Snyder-Robinson syndrome (SRS) results from mutations in spermine synthase (SMS), which converts the polyamine spermidine into spermine. Affecting primarily males, common manifestations of SRS include intellectual disability, osteoporosis, hypotonia, and seizures. Symptom management is the only treatment. Reduced SMS activity causes spermidine accumulation while spermine levels are reduced. The resulting exaggerated spermidine:spermine ratio is a biochemical hallmark of SRS that tends to correlate with symptom severity. Our studies aim to pharmacologically manipulate polyamine metabolism to correct this imbalance as a therapeutic strategy for SRS. Here we report the repurposing of 2-difluoromethylornithine (DFMO), an FDA-approved inhibitor of polyamine biosynthesis, in rebalancing spermid

SUBMITTER: Dr. Tracy, Murray Stewart 

PROVIDER: S-SCDT-10_15252-EMMM_202317833 | biostudies-other |

REPOSITORIES: biostudies-other